Researchers from Michigan State University’s College of Human Medicine are among a group investigating a drug that has the potential to not only alleviate Parkinson’s disease symptoms but also halt the disease’s progression.
Along with the Van Andel Research Institute and the Translational Genomics Research Institute, MSU researchers are focusing on the drug Fasudil, which is currently approved in Japan to improve blood flow to the brain in stroke victims and has shown similar positive outcomes in clinical trials in the U.S. Read the rest of the article here

